Related Experiment Video
Updated: Jul 20, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
[Interferon-beta response in multiple sclerosis associated with pre-treatment disability]
O Fernandez-Fernandez1, V E Fernandez-Sanchez, C Mayorga
1Instituto de Neurociencias Clínicas, Hospital Regional Universitario Carlos Haya, Málaga, Espana.
Aim:
To study pre-treatment clinical features and influence of neutralising antibodies (NABs) in clinical response to interferon-beta (IFNB).
Patients And Methods:
We analysed clinical characteristics and NABs to IFNB in 96 multiple sclerosis patients treated with IFNB. Clinical response was established by clinical criteria: = 1 relapse or an increase = 0.5 or 1 point in the Expanded Disability Status Scale (EDSS) score after one year of treatment compared with the year prior to IFNB therapy.
Results:
Baseline clinical characteristics were similar for responders and non-responders, except for a significantly higher baseline mean EDSS score in non-responders. Time-to-first-relapse was longer and the number of patients relapse-free was higher for NAB-negative patients, but we were unable to show an association with the disability status, probably due to sample size.
Conclusions:
Response to IFNB was significantly associated with pre-treatment disability measured by the EDSS. The presence of NABs to IFNB presented a delayed negative effect for relapses.
More Related Videos
Related Concept Videos
Multiple Sclerosis l: Introduction
Inhibitors of Viral Protein Synthesis
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

